Top 10 Leading Liquid Biopsy Companies in 2025
10 May, 2025

Liquid biopsy is an non-invasive diagnostic method that identifies cancer-associated genetic material, including circulating tumor DNA (ctDNA), RNA, or exosomes, in body fluids such as blood, urine, or saliva. In contrast to conventional tissue biopsies, which involve surgical procedures, liquid biopsy provides a safer, quicker, and more convenient option, enabling real-time tracking of cancer development and treatment response. It is particularly valuable in cases where tumors are hard to reach or when repeated sampling is needed. Liquid biopsy is widely used for early cancer detection, identifying mutations for targeted therapy, monitoring minimal residual disease, and predicting treatment resistance. Its applications span several cancer types, including lung, breast, colorectal, and prostate cancer.

Moreover, the method facilitates personalized medicine by enabling doctors to personalize treatments according to a patient's genetic makeup. With advancing technology, liquid biopsy is becoming a central tool in contemporary oncology, facilitating earlier intervention and better patient outcomes. The liquid biopsy market is expected to grow from US$ 4.29 billion in 2024 to approximately US$ 15.46 billion by 2033, expanding at a robust CAGR of 15.30% during the period 2025-2033.

The US liquid biopsy market is emerging fast as a result of advancements in non-invasive diagnostic technology. Liquid biopsy analyzes blood, urine, and other bodily fluids to identify cancer-specific biomarkers such as ctDNA and CTCs. It is more preferred over tissue biopsies because it minimizes the risk to patients and gives an all-rounded picture of the genetic makeup of tumors. The United States liquid biopsy market is expected to reach around US$ 4.25 billion by 2033, rising from US$ 1.21 billion in 2024 at a high CAGR of 14.99% from 2025 to 2033.

Drivers of market growth are increasing cancer diagnoses, higher healthcare awareness, advancements in genomics, and moving towards personalized medicine. Liquid biopsies improve the decision-making process for treatment and disease monitoring. The U.S. has leadership in this technology with a robust pipeline of firms and regulatory support by the FDA. The American Cancer Society estimates approximately 2,001,140 new cases of cancer and 611,720 cancer-related deaths in the U.S. during 2024.

Discover key trends, growth opportunities, and challenges shaping the Liquid Biopsy industry worldwide with Renub Research's latest market report. Get your free sample

List of Top 10 Liquid Biopsy Companies

F. Hoffmann-La Roche Ltd.

Establishment:  1896

Headquarters:  Switzerland

Website: www.roche.com

F. Hoffmann-La Roche Ltd (Roche) is a global biotechnology leader in in-vitro diagnostics and providing innovative solutions in major disease areas. It formulates and distributes drugs for diseases like cancer, autoimmune diseases, central nervous system disorders, eye diseases, infectious diseases, and respiratory diseases. Roche also offers in-vitro diagnostic solutions, tissue-based cancer diagnostics, and diabetes care solutions. The organization is engaged in active research with a focus on finding novel ways to prevent, diagnose, and treat numerous diseases. Roche provides hospitals, healthcare professionals, commercial laboratories, researchers, and pharmacists with its full range of products and services.

Bio-Rad Laboratories

Foundation: 1952

Headquarter: United States of America

Website: www.bio-rad.com

Bio-Rad Laboratories Inc. (Bio-Rad) is a worldwide developer, manufacturer, and distributor of instruments, software, consumables, and reagents for clinical diagnostics and the life sciences markets. Its wide-ranging product line consists of antibodies, autoimmune diagnostic kits, blood grouping systems, cell separation products, and digital PCR systems. Such products find applications in bioprocess analysis, cell and gene research, immunology, and mutation detection. Bio-Rad has a broad customer base consisting of research and academic institutions, hospitals, public health entities, diagnostic laboratories, and firms in the chemical, pharmaceutical, biotech, and food industries. Bio-Rad sells its products through direct sales, distributors, agents, brokers, and resellers with presence in the US, Germany, France, China, Singapore, and other regions.

Thermo Fisher Scientific Inc.

Establishment: 2006

Headquarters: United States of America

Website: www.thermofisher.com

Thermo Fisher Scientific Inc. (Thermo Fisher) is a global leader in providing analytical instruments, life sciences solutions, specialty diagnostics, and laboratory services. Its wide range of products includes laboratory equipment, instruments, clinical diagnostic products, chromatography and mass spectrometry systems, chemicals, cell culture products, and molecular biology products. Thermo Fisher provides its products to pharmaceutical and biotechnology firms, hospitals, clinical laboratories, academic research institutions, and government agencies. Its major brands are Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. The firm distributes its products through a global direct sales and customer service professional network, e-commerce sites, and third-party distributors.

Johnson & Johnson

Formation: 1886

Headquarters: United States of America

Website: www.jnj.com

Johnson & Johnson (J&J) is a worldwide health company dedicated to research, development, manufacturing, and marketing healthcare pharmaceuticals and medical devices. Functioning through a network of subsidiaries, J&J provides pharmaceutical therapies aimed at the treatment of immune disorders, oncology, neurological diseases, infectious diseases, cardiovascular, and metabolic disorders. Besides that, it also offers medical devices for use in cardiovascular health, orthopedics, neurovascular care, general surgery, and vision care. Its products are supplied to wholesalers, retailers, healthcare providers, and hospitals across the globe. J&J has manufacturing sites throughout the United States, Europe, Asia-Pacific, Africa, Latin America, and other parts of the Western Hemisphere, with global reach and supply capacity.

Biocept Inc.

Founding: 1997

Head Office: United States of America

Website: http://www.biocept.com/

Biocept Inc. is a molecular diagnostics firm that focuses on the development and commercialization of liquid biopsy cancer tests for detection and monitoring. The firm specializes in capturing and analyzing circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in blood and other bodily fluids, offering minimally invasive alternatives to traditional tissue biopsies. Biocept's proprietary Target Selector™ technology is employed for the detection and monitoring of a broad variety of cancers, including breast cancer, lung cancer, gastric cancer, colorectal cancer, and prostate cancer. Its tests help doctors make informed treatment choices by detecting particular genetic mutations and biomarkers. Biocept markets to hospitals, oncologists, and research institutions, mostly in the United States.

Guardant Health

Founding: 2012

Headquarters: United States of America

Website: guardanthealth.com

Guardant Health Inc. is a precision oncology firm dedicated to improving cancer care using innovative technologies. It designs and markets proprietary digital sequencing technology intended to detect particular genomic alterations. Its lead product, Guardant360, enables early cancer detection, residual disease monitoring, and recurrence tracking during treatment. Guardant Health's test portfolio also consists of GuardantOMNI, GuardantINFINITY, and GuardantINFORM. Guardant Health also provides a cloud-based data platform that enables liquid biopsy-driven genomic testing for individualized cancer treatment. Guardant Health has operations in various countries, including the United States, the Netherlands, Japan, and Singapore.

llumina, Inc.

Founding: 1998

Headquarters: United States of America

Website: www.illumina.com

Illumina Inc. is a top genomic sequencing and array-based technologies provider utilized for genetic analysis in consumer genomics, translational genomics, cancer research, and molecular diagnostics. Its diverse product portfolio consists of sequencing systems and tools, microarray kits and sequencing kits, molecular biology reagents, and corresponding consumables. Illumina also provides services for whole-genome sequencing, microarray analysis, as well as instrument consulting, maintenance, and training. Its clients are pharmaceutical and biotechnology corporations, universities and research institutions, clinical research groups, and genomics research organizations. Illumina distributes its products through a combination of direct marketing and distribution networks in various geographies such as the Americas, Europe, Asia-Pacific, Middle East, and Africa.

Laboratory Corporation of America Holdings

Formation: 1978

Headquarters: United States of America

Website: www.labcorp.com

Laboratory Corporation of America Holdings (LabCorp) is one of the fastest-growing clinical laboratory service providers with complete drug development solutions. The organization is specialized in creating and marketing a broad range of diagnostic technologies and testing services, such as core lab testing, esoteric and genomic testing. LabCorp provides general and specialty lab testing services, bone marrow analysis, HLA testing, DNA identification, forensic testing, paternity testing, and personalized medicine. LabCorp also provides full-service drug development support through its Covance division. Its customers are managed care organizations, government agencies, physicians, hospitals, pharmaceutical and biotechnology companies. LabCorp has an extensive network of patient service centers and laboratories in the U.S. and abroad, including those in Belgium, China, Singapore, and the UK.

QIAGEN N.V.

Founding: 1984

Head Office: Netherlands

Website: www.qiagen.com

Qiagen NV (Qiagen) is a world leader in molecular testing solutions. Qiagen supplies technologies used for the extraction and processing of proteins, DNA, and RNA from different sample materials, including blood and tissues. Qiagen builds assay technology to detect genetic data in tumours and pathogens, and also bioinformatics applications for interpreting advanced genomic data. Its automation tools automate molecular tests procedures in a lab. Qiagen caters to a wide variety of markets such as human healthcare, veterinary diagnostics, forensics, food safety, pharmaceuticals, and life sciences research. Both directly and through independent distributors, products are sold. The company is located in the Americas, Europe, the Middle East, Africa, and Asia-Pacific.

Exact Sciences Corporation

Foundation: 1995

Headquarter: United States of America

Website: www.exactsciences.com

Exact Sciences Corp (Exact Sciences) is a molecular diagnostic company engaged in developing cutting-edge tests for cancer detection. Its lead product, Cologuard, is a US FDA-cleared, non-invasive, stool-based DNA screening test that is used for early detection of colorectal cancer and pre-cancer. It uses a multi-target approach to identify DNA and hemoglobin biomarkers related to colorectal cancer. Further, Exact Sciences provides Oncotype DX gene expression tests for breast, prostate, and colon cancer, and Oncotype DX AR-V7 Nucleus Detect, a liquid test for prostate cancer that is advanced. The company runs manufacturing and lab space in Madison, Wisconsin, where it analyzes Cologuard tests.